Purpose: To determine the risk of endophthalmitis in eyes undergoing intravitreal injections (IVIs) of anti-VEGF based on cumulative number of injections per eye.
Design: Retrospective cohort study.
Participants: Patients from a single center undergoing IVIs of ranibizumab, aflibercept, or bevacizumab.
Methods: Eyes were divided into quartiles based on injection number causative of endophthalmitis between January 1, 2011, and June 1, 2022.
Main Outcome Measures: Interquartile clinical outcomes and cumulative risk of endophthalmitis per injection and per eye.
Results: A total of 43 393 eyes received 652 421 anti-VEGF injections resulting in 231 endophthalmitis cases (0.035% per injection, 1 in 2857), of which 215 were included. The cumulative endophthalmitis risk increased from 0.0018% (1 in 55 556) after 1 injection to 0.013% (1 in 7692) after 11 injections (0.0012 percentage point change), versus 0.014% (1 in 7143) after 12 injections to 0.025% (1 in 4000) after 35 injections (0.00049 percentage point change), versus 0.025% (1 in 4000) after 36 injections to 0.031% (1 in 3226) after 66 injections (0.00017 percentage point change), versus 0.031% (1 in 3226) after 63 injections to 0.033% (1 in 3030) after 126 injections (0.000042 percentage point change) (P < 0.001). Likewise, the cumulative endophthalmitis risk per eye increased from 0.028% (1 in 3571) to 0.20% (1 in 500) between injections 1 and 11 (0.018 percentage point change), versus 0.21% (1 in 476) to 0.38% (1 in 263) between injections 12 and 35 (0.0075 percentage point change), versus 0.38% (1 in 263) to 0.46% (1 in 217) between injections 36 and 66 (0.0026 percentage point change), versus 0.46% (1 in 217) to 0.50% (1 in 200) between injections 67 and 126 (0.00063 percentage point change) (P < 0.001).
Conclusions: The cumulative endophthalmitis risk per injection and per eye increased with greater number of injections received but appeared to do so at a higher rate during earlier injections and at a lower rate further into the treatment course.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ophtha.2023.12.033 | DOI Listing |
Front Artif Intell
January 2025
Department of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.
Introduction: Active learning can significantly decrease the labeling cost of deep learning workflows by prioritizing the limited labeling budget to high-impact data points that have the highest positive impact on model accuracy. Active learning is especially useful for semantic segmentation tasks where we can selectively label only a few high-impact regions within these high-impact images. Most established regional active learning algorithms deploy a static-budget querying strategy where a fixed percentage of regions are queried in each image.
View Article and Find Full Text PDFIndian Dermatol Online J
December 2024
The Venkat Centre for Advanced Dermatology, Plastic Surgery and ENT, Bengaluru, Karnataka, India.
Background: Trichoscopy is a simple, noninvasive tool to help in the diagnosis of various hair and scalp disorders. There is paucity of data on the normal trichoscopic parameters of hair density and diameter in the Indian population.
Aim: The aim of this study was to establish the trichoscopic patterns of hair and scalp in healthy Indian males and to provide a framework for future reference.
Plast Reconstr Surg Glob Open
January 2025
Plastic, Reconstructive and Aesthetic Surgery Department, Yeditepe University Hospital, Istanbul, Turkey.
Background: Facial aging involves multifactorial changes affecting the bone, superficial musculoaponeurotic system, fat pads, and skin, primarily manifesting as the downward displacement of these structures. The transtemporal endoscopic deep plane face lift (TEDPF) suggests a vertical lifting method, targeting these issues without a preauricular incision.
Methods: A retrospective study was conducted on 140 patients (133 women and 7 men) 33-67 years of age who underwent TEDPF from February 2020 to March 2023.
Biomark Res
January 2025
State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Heart failure (HF) remains a significant public health challenge globally. This study aims to systematically analyze the global HF disease burden from 1990 to 2021 across temporal, spatial, and demographic dimensions to provide evidence for targeted prevention and control strategies.
Methods: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed the global HF burden through prevalent cases, years lived with disability (YLDs), and age-standardized rates per 100,000 population.
J Cardiol
January 2025
Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
Background: Alcohol septal ablation (ASA) is used to treat drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). Intraprocedural echocardiography is essential for identifying the septal area perfused by each septal branch; however, its role in determining the procedural endpoint of ASA remains unclear. This retrospective study aimed to evaluate the impact of intraprocedural echocardiographic findings on clinical outcomes and left ventricular pressure gradient (LVPG) after ASA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!